Merck Patent Gmbh

Taro Pharmaceuticals Inc.

Ares Trading S.a.

Sumitomo Pharma Oncology, Inc.

Aquinox Pharmaceuticals (Canada) Inc.

Jeyaprakashnarayanan Seenisamy

Curtis Harwig

Mahesh Narayan Keregadde

Jeremy D Pettigrew

Jennifer Cross

Andreas Goutopoulos

Timo Heinrich

Richard Dana Caldwell

Theresa L Johnson

Dominique Swinnen

Brian A Sherer

Hui Qiu

Lesley Liu-Bujalski

Reinaldo Jones

Constantin Neagu

Pascale Gaillard

Justin Potnick

Annie Cho Won

Anna Gardberg

Karthikeyan Iyanar

Dieter Dorsch

David J Bearss

Steven L Warner

Frank Zenke

Guenter Hoelzemann

Yufang Xiao

Srinivasa R Karra

Adam Siddiqui-Jain

Stefano Crosignani

Mathilde Muzerelle

Clifford J Whatcott

Mireille Krier

Ansgar Wegener

Oliver Poeschke

Michael Busch

Manja Friese-Hamim

Federica Morandi

Jayashankaran Jayadevan

Samir Satish Kher

Lakshindra Chetia

A process can be used for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide.

Process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide

Compounds of formula (1): wherein, R, R, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.

Indene derivatives useful in treating pain and inflammation

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X, X, R, R, R, R, R, R, R, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.

Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Compounds of formula (I) wherein, R, R, R, R, R4b and Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. 

Compounds of formula (I): wherein, R, R, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. 

Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.

Heteroaryl compounds as BTK inhibitors and uses thereof

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

Described are cyclic amide compounds of the formula (I): in which R, R, R, R, R, R, X and Y have the meanings as described. The compounds are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.

Cyclic amides as MetAP-2 inhibitors

This invention is directed to methods of preparing AQX-1125 having the formula:  This invention is also directed to intermediates utilized in the methods of preparing AQX-1125.

Synthesis of a substituted indene derivative

The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. 

Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Compounds of the formula I in which X, Rand Rhave the meanings indicated in Claimare inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

Imidazopyrimidine derivatives

The present invention relates to alpha hydroxy amides including compounds of formula I: and related compounds and their use in the prophylaxis and treatment of inflammatory disorders and diseases, wherein T, T, W and Rhave the meanings given in claim

Alpha hydroxy amides

The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

Quinoline derivatives and their use in neurodegenerative diseases

Growing community of inventors

Bengaluru, India

Jeyaprakashnarayanan Seenisamy